CLEERLY NAMED TO THE 2021 CB INSIGHTS DIGITAL HEALTH 150 List of Most Innovative Digital Health Startups
NEW YORK, December 8, 2021 — CB Insights today named Cleerly to its third annual Digital Health 150, which showcases the 150 most promising private digital health companies in the world. This year’s Digital Health 150 was unveiled live during CB Insights’ annual Future of Health event.
The 2021 Digital Health 150 cohort has raised roughly $14.9B in aggregate funding across 522 deals since 2016, and includes startups at various investment stages of development, from early-stage to well-funded unicorns. Companies this year include startups working on data integration & analytics, hybrid virtual / in-person care, digital therapeutics, clinical intelligence, and more.
“This year’s Digital Health 150 is one of our most expansive yet, spotlighting 16 categories including virtual care, clinical trials tech, and workflow automation, as well as adding new categories such as home health tech and computer-aided imaging,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “Last year’s class has seen more than 20 exits, raised an additional $18.6B in aggregate funding, and announced over 250 partnerships since being recognized, and we’re excited to see the future success of this year’s winners.”
Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from a pool of over 11,000 companies, including applicants and nominees. They were chosen based on several factors, including data submitted by the companies, company business models and momentum in the market, and Mosaic scores, CB Insights’ proprietary algorithm that measures the overall health and growth potential of private companies.
Cleerly offers a new and disruptive paradigm for the discovery, assessment, and prevention of heart disease. With a focus on finding and treating a person’s disease long before they experience the late-stage symptoms of a heart attack, Cleerly is supported by more than a decade of some of the largest and most significant clinical trials in cardiology to date. Cleerly’s technology pairs cardiac CT angiography and a comprehensive AI-based solution to discover, characterize, and stage a person’s disease while supporting users with an easy-to-understand user interface and patient resources.
“Advanced imaging has been key to diagnosing and preventing the most common causes of cancer for years, but we’re not using it yet to prevent the most common cause of death. We use 3D mammograms, colonoscopies and lung CT scans to find and prevent breast, colon, and lung cancer, but we have not had to date analogous capabilities for the world’s number one killer – heart disease,” said James K. Min, MD FACC, and founder and CEO of Cleerly. “Through the application of latest-generation artificial intelligence that is constantly being refined with our unprecedented volume of accruing and exclusive clinical data, Cleerly is bringing heart disease diagnosis and prevention into the twenty-first century.”
2021 Digital Health 150 Investment Highlights:
Unicorns: 17 of the 150 companies (11%) are valued at or above $1B as of their latest funding rounds.
Funding trends: In 2021 year-to-date (YTD), these 150 private companies have raised $9.2B in equity funding across 153 deals (as of 11/19/21).
Mega-rounds: Since 2020, there have been 39 mega-round ($100M+) equity investments to this year’s Digital Health 150, with 31 (79%) of them taking place in 2021 YTD.
Global representation: 23% of the 2021 Digital Health 150 are based outside the US. After the US, the UK is home to the most Digital Health 150 companies (9), followed by India (4). This year’s winners are based in 18 countries, including China, Israel, Nigeria, Germany, Argentina, and New Zealand.
Top VC investor: General Catalyst is the most active investor in this year’s Digital Health 150 companies, having invested in 39 deals since 2016.
THE DIGITAL HEALTH 150 COMPANIES (IN ALPHABETICAL ORDER):
DiA Imaging Analysis
Elligo Health Research
Emocha Mobile Health
Medically Home Group
MEDIA CONTACT email@example.com
RESOURCES Cleerly-CB-Insights-Digital-Health-150 Cleerly Named to the 2021 CB Insights Digital Health 150 Download image
ABOUT CB INSIGHTS CB Insights builds software that enables the world’s best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.
ABOUT CLEERLY Cleerly is the company creating a new standard of care for heart disease. Through value-based precision diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: https://www.cleerlyhealth.com.